FDA Targets Unapproved Diabetes Drugs

FDA to Restrict GLP-1 Drugs, Pentagon Cuts Ties with Harvard

WASHINGTON, D.C. - February 7, 2026 - The U.S. Food and Drug Administration (FDA) announced its intent to restrict GLP-1 active pharmaceutical ingredients (APIs) used in non-FDA-approved compounded drugs, while the Pentagon simultaneously severed ties with Harvard University, ending military training programs. These developments were revealed on Friday, as reported by multiple news outlets.

The FDA's actions, according to a statement from Commissioner Martin A. Makary, M.D., M.P.H., are designed to protect consumers from drugs whose quality, safety, and efficacy cannot be verified. The FDA is particularly concerned about mass-marketed compounded drugs offered by companies like Hims and Hers, which are positioned as alternatives to FDA-approved medications. The agency also plans to combat misleading advertising and marketing practices.

In a separate announcement, the Pentagon stated it was ending all military training, fellowships, and certificate programs with Harvard University. Defense Secretary Pete Hegseth cited concerns that Harvard "no longer meets the needs" of the military, marking the latest escalation in a prolonged dispute between the Trump administration and the Ivy League institution.

In other news, NPR reported on concerns for an Iranian-American held in Evin prison in Tehran, as indirect talks between the U.S. and Iran regarding the country's nuclear program continue. Ryan Fayhee, lawyer for journalist Abdolreza Valizadeh, expressed his worries about his client's situation.

Additionally, Danish veterans of the Iraq war are seeking an apology from President Trump over his stance on Greenland, according to NPR.

Finally, a correction was published in Nature regarding an article on environmentally driven immune imprinting and allergy protection. The original article, published on January 28, 2026, had interchanged images in its extended data figures. The corrected versions are now available.